EVEREST MED-B (01952.HK) announced that its product Budesonide enteric-coated capsules 'Nai Fu Kang' was prescribed the first prescription in Hong Kong at Hong Kong Adventist Hospital on December 16, making it the third commercialization region after China and Singapore this year.

The product was approved by the Hong Kong Department of Health in May this year for the treatment of adult patients with primary IgA nephropathy at risk of disease progression and was recently included in the national medical insurance pharmaceutical catalog. EVEREST MED's CEO Luo Yongqing stated that IgA nephropathy is prevalent in Asia, with approximately 5 million IgA nephropathy patients in China, and over 100,000 new cases diagnosed each year, indicating a significant unmet clinical need. The issuance of the first prescription for Nai Fu Kang in Hong Kong further expands its clinical coverage, providing innovative etiology treatment options for more patients.